BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35133217)

  • 1. "1,000 conversations I'd rather have than that one:" A qualitative study of prescriber experiences with opioids and the impact of a prescription drug monitoring program.
    Zavodnick J; Wickersham A; Petok A; Worster B; Leader A
    J Addict Dis; 2022; 40(4):527-537. PubMed ID: 35133217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physicians' Perspectives Regarding Prescription Drug Monitoring Program Use Within the Department of Veterans Affairs: a Multi-State Qualitative Study.
    Radomski TR; Bixler FR; Zickmund SL; Roman KM; Thorpe CT; Hale JA; Sileanu FE; Hausmann LRM; Thorpe JM; Suda KJ; Stroupe KT; Gordon AJ; Good CB; Fine MJ; Gellad WF
    J Gen Intern Med; 2018 Aug; 33(8):1253-1259. PubMed ID: 29520747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physician attitudes and experiences with Maryland's prescription drug monitoring program (PDMP).
    Lin DH; Lucas E; Murimi IB; Jackson K; Baier M; Frattaroli S; Gielen AC; Moyo P; Simoni-Wastila L; Alexander GC
    Addiction; 2017 Feb; 112(2):311-319. PubMed ID: 27658522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prescription drug monitoring program in a multifactorial approach to the opioid crisis: PDMP data, Pennsylvania, 2016-2020.
    Adalbert JR; Syal A; Varshney K; George B; Hom J; Ilyas AM
    BMC Health Serv Res; 2023 Apr; 23(1):364. PubMed ID: 37046254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between statewide prescription drug monitoring program (PDMP) requirement and physician patterns of prescribing opioid analgesics for patients with non-cancer chronic pain.
    Lin HC; Wang Z; Boyd C; Simoni-Wastila L; Buu A
    Addict Behav; 2018 Jan; 76():348-354. PubMed ID: 28898808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspectives of opioid prescribers in overdose hotspots and coldspots, Massachusetts, 2019.
    Santelices C; Pustz J; Chase C; Kim JY; Stopka TJ
    Subst Use Misuse; 2023; 58(8):1069-1074. PubMed ID: 37073632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of mandatory prescription drug monitoring program (PDMP) use laws on prescriber registration and use and on risky prescribing.
    Strickler GK; Zhang K; Halpin JF; Bohnert ASB; Baldwin GT; Kreiner PW
    Drug Alcohol Depend; 2019 Jun; 199():1-9. PubMed ID: 30954863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in opioid and other analgesic prescribing following voluntary and mandatory prescription drug monitoring program implementation: A time series analysis of early outcomes.
    Nielsen S; Picco L; Russell G; Pearce C; Andrew NE; Lubman DI; Bell JS; Buchbinder R; Xia T
    Int J Drug Policy; 2023 Jul; 117():104053. PubMed ID: 37209441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in opioid agonist treatment initiation among people prescribed opioids for pain following voluntary and mandatory prescription drug monitoring program implementation: A time series analysis.
    Picco L; Xia T; Bell JS; Pearce C; Buchbinder R; Lubman DI; Nielsen S
    Drug Alcohol Rev; 2023 Nov; 42(7):1639-1646. PubMed ID: 37798947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription Drug Monitoring Program Use: National Dental PBRN Results.
    McCauley JL; Gilbert GH; Cochran DL; Gordan VV; Leite RS; Fillingim RB; Brady KT;
    JDR Clin Trans Res; 2019 Apr; 4(2):178-186. PubMed ID: 30931705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of the Use of a Mandatory Prescription Drug Monitoring Program With Prescribing Practices for Patients Undergoing Elective Surgery.
    Stucke RS; Kelly JL; Mathis KA; Hill MV; Barth RJ
    JAMA Surg; 2018 Dec; 153(12):1105-1110. PubMed ID: 30140927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescription drug monitoring program design and function: A qualitative analysis.
    Rutkow L; Smith KC; Lai AY; Vernick JS; Davis CS; Alexander GC
    Drug Alcohol Depend; 2017 Nov; 180():395-400. PubMed ID: 28978492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating Emergency Department Opioid Prescribing Behaviors After Education About Mandated Use of the Pennsylvania Prescription Drug Monitoring Program.
    Martello J; Cassidy B; Mitchell A
    J Addict Nurs; 2018; 29(3):196-202. PubMed ID: 30180006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Prescription Drug Monitoring Program Use With Opioid Prescribing and Health Outcomes: A Comparison of Program Users and Nonusers.
    Deyo RA; Hallvik SE; Hildebran C; Marino M; Springer R; Irvine JM; O'Kane N; Van Otterloo J; Wright DA; Leichtling G; Millet LM; Carson J; Wakeland W; McCarty D
    J Pain; 2018 Feb; 19(2):166-177. PubMed ID: 29054493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid Prescribing Patterns and Patient Outcomes by Prescriber Type in the Oregon Prescription Drug Monitoring Program.
    Fink PB; Deyo RA; Hallvik SE; Hildebran C
    Pain Med; 2018 Dec; 19(12):2481-2486. PubMed ID: 29155988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Provider Prescription Drug Monitoring Program Utilization and Self-Auditing-A Pilot Study.
    Brown WC; Whitted K
    J Dr Nurs Pract; 2020 Jul; 13(2):142-147. PubMed ID: 32817503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary Care Implementation of a Mandatory Prescription Drug Monitoring Program in New York City.
    Chernick R; Allen B; Harocopos A
    J Behav Health Serv Res; 2022 Apr; 49(2):122-133. PubMed ID: 34426933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Postoperative Opioid Prescriptions Before and After Implementation of a Mandatory Prescription Drug Monitoring Program.
    Shenoy R; Wagner Z; Kirkegaard A; Romanelli RJ; Mudiganti S; Mariano L; Martinez M; Zanocco K; Watkins KE
    JAMA Health Forum; 2021 Oct; 2(10):e212924. PubMed ID: 35977161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How Are Real-time Opioid Prescribing Cognitions by Emergency Providers Influenced by Reviewing the State Prescription Drug Monitoring Program?
    Landau A; Lynch M; Callaway C; Suffoletto B
    Pain Med; 2019 May; 20(5):955-960. PubMed ID: 29762757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mandatory Review of Prescription Drug Monitoring Program Before Issuance of a Controlled Substance Results in Overall Reduction of Prescriptions Including Opioids and Benzodiazepines.
    Manders L; Abd-Elsayed A
    Pain Physician; 2020 Jun; 23(3):299-304. PubMed ID: 32517396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.